J&J Unit Fights To Save Remicade Patent At Fed. Circ.
A Johnson & Johnson subsidiary urged the Federal Circuit on Tuesday to reverse a decision invalidating a patent on its blockbuster autoimmune disease drug Remicade for double-patenting, saying the finding conflicts...To view the full article, register now.
Already a subscriber? Click here to view full article